Navigation Links
Global Markets and Technologies for Molecular Imaging Devices
Date:9/2/2014

IMAGING DEVICE MARKET SHARE IN EUROPE BY TYPE, 2018
(%) 158
TABLE 77 EUROPEAN MARKET FOR MOLECULAR IMAGING DEVICES BY COMPANY,
2013 (%) 160
TABLE 78 MARKET FOR MOLECULAR IMAGING DEVICES IN FRANCE, THROUGH 2018 161
TABLE 79 MOLECULAR IMAGING DEVICES REVENUE BY TYPE IN FRANCE, THROUGH
2018 ($ MILLIONS) 162
TABLE 80 MARKET FOR MOLECULAR IMAGING DEVICES IN GERMANY, THROUGH
2018 ($ MILLIONS/UNITS) 163
TABLE 81 MOLECULAR IMAGING REVENUE BY DEVICE IN GERMANY, 2013 AND 2018
($ MILLIONS) 164
TABLE 82 MARKET FOR MOLECULAR IMAGING DEVICES IN ITALY, THROUGH 2018 ($
MILLIONS/UNITS) 165
TABLE 83 MOLECULAR IMAGING REVENUE BY DEVICE IN ITALY, 2013 AND 2018 ($
MILLIONS) 166
TABLE 84 MARKET FOR MOLECULAR IMAGING DEVICES IN SPAIN, THROUGH 2018 ($
MILLIONS/UNITS) 167
TABLE 85 MOLECULAR IMAGING REVENUE BY DEVICE TYPE IN SPAIN, THROUGH
2018 ($ MILLIONS) 168
TABLE 86 MARKET FOR MOLECULAR IMAGING DEVICES IN THE U.K., THROUGH 2018
($ MILLIONS/UNITS) 169
TABLE 87 MOLECULAR IMAGING REVENUE BY DEVICE IN THE U.K., 2013 AND 2018
($ MILLIONS) 170
TABLE 88 MARKET FOR MOLECULAR IMAGING DEVICES IN THE SCANDINAVIA
REGION, THROUGH 2018 ($ MILLIONS/UNITS) 171
TABLE 89 MOLECULAR IMAGING REVENUE BY DEVICE IN THE SCANDINAVIA REGION,
2013 AND 2018 ($ MILLIONS) 172
TABLE 90 MARKET FOR MOLECULAR IMAGING DEVICES IN THE BENELUX REGION,
THROUGH 2018 ($ MILLIONS/UNITS) 173
TABLE 91 MOLECULAR IMAGING REVENUE BY DEVICE IN THE BENELUX REGION,
2013 AND 2018 ($ MILLIONS) 175
TABLE 92 HEALTHCARE GOALS BY YEAR 179
TABLE 93 INDIA'S POPULATION DEMOGRAPHIC FIGURES FOR 2013 180
TABLE 94 INDIA'S OLDER POPULATION BY AGE GROUP 2000–2050 181
TABLE 95 JAPAN'
'/>"/>
SOURCE ReportBuyer
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25

Related medicine technology :

1. Bariatric Surgery: Global Markets for Services and Devices
2. Acute Heart Failure Global Clinical Trials Review, H2, 2014
3. Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden
4. Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke
5. Avanir Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Conference
6. Abaxis, Inc. to Present at the Morgan Stanley Global Healthcare Conference
7. Hologic to Present at the Morgan Stanley Global Healthcare Conference
8. Mast Therapeutics To Present At The Rodman And Renshaw 16th Annual Global Investment Conference On September 9th
9. Veracyte to Present at the Morgan Stanley Global Healthcare Unplugged Conference 2014
10. CAGR of 10.1% Global Biological Drugs Market - Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 to 2020: Report by MarketResearchReports.Biz
11. Contract Research Organization WCCT Global Celebrates Being Named as One of the Fastest Growing Companies in America
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: AST), ... of regenerative medicine, today announced that the third ... -based Rush University Medical Center in a ... doses of AST-OPC1 (oligodendrocyte progenitor cells) in newly ... spinal cord injury (SCI). This represents the final ...
(Date:8/31/2015)... N.J. and STAMFORD, Conn. ... pharmaceutical subsidiary of Eisai Co., Ltd., and Purdue Pharma ... worldwide collaboration agreement for the development and commercialization of ... orexin receptor antagonist entering Phase III clinical development for ... terms of the agreement, Eisai and Purdue Pharma will ...
(Date:8/31/2015)... , Aug. 31, 2015 Bionomics Limited ... and development of innovative therapeutics for the treatment of ... today announced that its BNC101 IND submission has passed ... Bionomics plans to initiate a Phase 1 clinical trial ... with metastatic pancreatic cancer prior to 31 December 2015. ...
Breaking Medicine Technology:Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 6Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 2Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 3Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 4Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 5Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 2Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 3Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 4
... multiple sclerosis, remained relapse-free after three years of treatment ... active brain lesions - the ... - MS, a devastating disease causing progressive disability, affects 2.5 ... including many young adults - FTY720 regulatory filings planned before ...
... basis of methotrexate,resistance and differences in methotrexate response, ... analysis,of the genetic determinants of resistance to the ... could offer a,pathway to predicting such resistance and ... Children,s Research Hospital study., Besides its use ...
Cached Medicine Technology:FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 2FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 3FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 4FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 5FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 6St. Jude Gene Study Reveals Basis of Anti-Cancer Drug Resistance in Childhood Leukemia 2St. Jude Gene Study Reveals Basis of Anti-Cancer Drug Resistance in Childhood Leukemia 3St. Jude Gene Study Reveals Basis of Anti-Cancer Drug Resistance in Childhood Leukemia 4
(Date:8/31/2015)... ... August 31, 2015 , ... ... a one-day event geared to patients and family members, medical professionals, and researchers, ... regional mesothelioma experts. The conference is a collaborative effort between the Mesothelioma ...
(Date:8/31/2015)... ... August 31, 2015 , ... Coast Dental Vista ... 5, 2015, from 11 a.m. to 3 p.m. near Albertsons in the Foothill Center, ... to meet Dr. Ofelia Rivera and Dr. Jay Lopp. Call (760) 208-2518 for more ...
(Date:8/31/2015)... ... September 01, 2015 , ... ... for traumatic brain injury with emphasis on transcranial near-infrared laser phototherapy ”. , ... Traumatic brain injury has been largely untreatable - with mostly palliative treatments only ...
(Date:8/31/2015)... ... 31, 2015 , ... NJ Top Docs Presents, Dr. Michael Betsy! Dr. Betsy has been ... Jersey, Dr. Michael Betsy graduated from Don Bosco Prep in 1990 and was Class Salutatorian. ... in both sports in his senior year. He was inducted into the National Honor ...
(Date:8/31/2015)... ... 31, 2015 , ... How can healthcare meet the challenge ... , In a commentary for The American Journal of Managed Care , ... efficacy,” which would bind parties together in agreements to intervene at the earliest ...
Breaking Medicine News(10 mins):Health News:New York Experts on Mesothelioma Come Together at Memorial Sloan Kettering Cancer Center 2Health News:New York Experts on Mesothelioma Come Together at Memorial Sloan Kettering Cancer Center 3Health News:Discover How to Replace Missing Teeth, Reduce Cavities, and Restore Oral Health During Coast Dental’s Open House in Vista, CA on Sept. 5, 2015 2Health News:Discover How to Replace Missing Teeth, Reduce Cavities, and Restore Oral Health During Coast Dental’s Open House in Vista, CA on Sept. 5, 2015 3Health News:Near-Infrared Laser Phototherapy for Brain Injury published by Dove Medical Press 2Health News:Near-Infrared Laser Phototherapy for Brain Injury published by Dove Medical Press 3Health News:NJ Top Docs Presents, Dr. Michael Betsy! 2Health News:NJ Top Docs Presents, Dr. Michael Betsy! 3Health News:How “Clinical Efficacy” Can Rein in Healthcare Costs 2Health News:How “Clinical Efficacy” Can Rein in Healthcare Costs 3
... who are overweight or obese have increased blood pressure ... risk of kidney damage previously found in this group ... at the American Society of Nephrology's 39th Annual Meeting ... demonstrated that filtration pressure in the kidney was higher ...
... bypass surgery for morbid obesity have increased risk factors ... paper being presented at the American Society of Nephrology's ... ,'Gastric bypass surgery appears to lead to changes ... the formation of kidney stones,' comments Dr. Rajiv Kumar ...
... three-day yagna-fire worship-with 1,000 pyres began Friday here to ward ... ,Amid chanting of Vedic hymns by Hindu priests from across ... the ritual was performed with the lighting of a large ... Railway near here. ,The yagna, organised by NGO ...
... virtually crippled Saturday as over 300 doctors went on a ... them //by relatives of a patient who died allegedly due ... institution-struck work in the state-run Lok Nayak Jai Prakash (LNJP) ... 50 relatives of the patient stormed the emergency ward and ...
... diabetes who have repeated panic attacks are less likely ... severe health complications //and poorer quality of life, a ... Ph.D., a researcher with Group Health Cooperative in Seattle, ... with more poorly controlled glucose, more diabetes symptom, and ...
... A new drug has been approved in Scotland for the ... named Arimidex seems to be beneficial // specifically in treating ... an aromatase inhibitor that works by inhibiting the oestrogen production ... are expected to benefit from the use of this drug. ...
Cached Medicine News:Health News:Kidney Blood Flow May Explain Increased Long-Term Risks for Obese Kidney Donors 2Health News:Gastric Bypass Surgery May Lead to Increased Kidney Stone Risk 2Health News:Panic Attacks Can Increase Complications in Diabetes Patients 2
The Atria 6100 delivers the highest level of clinical performance while incorporating cutting-edge technology to streamline clinic workflow. It offers timely, high-quality, and accurate ECG results c...
The CSV-1000ETDRS10% test face presents the standard ETDRS test at a contrast level of 10%. This test is widely used in clinical studies for the evaluation of refractive surgery and contact lenses....
The CSV-1000SLanC test face provides the same tests as the standard CSV-1000S, except that the acuity test is presented in Landolt C format. , ,This test is very useful when testing patients who cann...
... CSV-1000E contrast sensitivity chart test face is the ... world. This test provides for four (4) rows ... of 8 ft (2.5 meters), these gratings test ... 18 cycles/degree. The CSV-1000E provides a full contrast ...
Medicine Products: